Table 5.
Sequential systemic treatments after failure of Lenvatinib or Sorafenib in the propensity score-matched cohort.
| Variables | All, n=210 | Lenvatinib, n=70 | Sorafenib, n=140 | P-value |
|---|---|---|---|---|
| Treatment Ongoing, n (%) | 16 (7.6) | 12 (17.1) | 4 (2.9) | <0.001 |
| Treatment Stop, n (%) | 194 (92.4) | 58 (82.9) | 136 (97.1) | <0.001 |
| Post-treatment, n (%)† | 103 (53) | 25 (43.1) | 78 (57.4) | 0.069 |
| Second-line systemic treatment, n(%)† | 86 (44.3) | 21 (36.2) | 65 (47.8) | 0.02 |
| Regorafenib | 34 | 1 | 33 | |
| Lenvatinib, | 13 | 0 | 13 | |
| Carbozantinib | 3 | 2 | 1 | |
| Nivolumab, | 16 | 3 | 13 | |
| Atezolizumab plus Bevacizumab |
5 | 5 | 0 | |
| Chemotherapy | 12 | 9 | 3 | |
| Others‡ | 3 | 1 | 2 | |
| Third-line systemic therapy, n (%) | 21 (10) | 2 (3.4) | 19 (14) | |
| Regorafenib | 2 | 0 | 2 | |
| Lenvatinib | 5 | 0 | 5 | |
| Nivolumab | 8 | 2 | 6 | |
| Pembrolizumab | 2 | 0 | 2 | |
| Chemotherapy | 4 | 0 | 4 | |
| Forth-line systemic therapy, n (%) | 2 (0.9) | 0 (0) | 2 (1.5) | |
| Lenvatinib | 1 | 0 | 1 | |
| Nivolumab | 1 | 0 | 1 |
†The proportion was calculated in patients who stopped lenvatinib or sorafenib.
‡Others: Two patients received thalidomide and one patient received oral 5-Flurouracie, respectively.